JOC The Journal of Organic Chemistry

Article

pubs.acs.org/joc

Design, Synthesis, and Antibacterial Activities of Conformationally Constrained Kanamycin A Derivatives

Wenxuan Zhang,[†] Ying Chen,[†] Qingzhao Liang,[†] Hui Li,[†] Hongwei Jin,[‡] Liangren Zhang,[‡] Xiangbao Meng,*,[†] and Zhongjun Li*,[†]

[†]Department of Chemical Biology and [‡]Department of Medicinal Chemistry, School of Pharmaceutical Sciences, The State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China

Supporting Information



ABSTRACT: A series of conformationally constrained kanamycin A derivatives with a 2′-hydroxyl group in ring I and a 5-hydroxyl group in ring II tethered by carbon chains were designed and synthesized. Pivotal 5,2′-hydroxyl groups were exposed, and the kanamycin A intermediate was synthesized from 5, 2′, 4″, 6″-di-*O*-benzylidene-protected tetraazidokanamycin A. Cyclic kanamycin A derivatives with intramolecular 8-, 9-, 10-, and 11-membered ethers were then prepared by cesium carbonate mediated Williamson ether synthesis or a ring-closing metathesis reaction. The kanamycin A derivatives were assayed against both susceptible and resistant bacterial strains. Although no derivative showed better antibacterial activities than kanamycin A, the antibacterial activities of these cyclic kanamycin A derivatives indeed varied with the length of the bridge. Moreover, different variations of activities were observed between the susceptible and resistant bacterial strains. More tightly constrained derivative **2** with a one-carbon bridge showed better activity than the others against susceptible strains, but it was much less effective for resistant bacterial strains than derivative **3** with a two-carbon bridge and derivative **6** with an unsaturated four-carbon bridge.

■ INTRODUCTION

Aminoglycosides are frequently prescribed broad spectrum antibiotics that have been used clinically for 70 years. However, the emergence of resistant bacteria is a threat for their use. One of the major causes of bacterial resistance is the enzymatic modification of the antibiotics.[1] The aminoglycoside-modifying enzymes can be broadly classified as *N*-acetyltransferases (AACs), *O*-adenyl transferases (ANTs), and *O*-phosphotransferases (APHs). Various strategies have been investigated to overcome the resistance.[2] Over the past decade, many structural analogues of natural aminoglycosides have been designed and synthesized, and some of the structures showed considerable antibacterial activities.[3]

Neamine (**1a**) is a conserved pseudodisaccharide that constitutes the core structures of many aminoglycosides such as neomycin B (**1b**), paromomycin (**1c**), kanamycin A (**1d**), and kanamycin B (**1e**) (Figure 1). Among the natural aminoglycosides containing the neamine motif, neomycin B and paromomycin have a 4,5-disubstitution on 2-deoxystreptamine (2-DOS, ring II), while kanamycin has a 4,6-disubstitution on 2-deoxystreptamine. Herein we report the design, synthesis and biological evaluation of conformationally constrained kanamycin A analogues through the linkage of 5- and 2′-hydroxyl groups.

■ RESULTS AND DISCUSSION

Design. The 3D structures of kanamycin A in complex with 16S RNA A-site and aminoglycoside-modifying enzymes show that the conformations of kanamycin A recognized by the 16S RNA A-site and the enzymes are different.[4] Indeed, this detailed structural information has already provided insights for the rational design of new aminoglycoside analogues.

Asensio and co-workers have developed a strategy to overcome bacterial resistance with conformationally locked neomycin B (**1b**).[5a] Neomycin B derivative with a methylene bridge between the 2′-NH_2 of ring I and 5″-OH of ring III represents an improved activity against bacteria expressing *Staphylococcus aureus* ANT(4′). Hanessian's group also synthesized paromomycin (**1c**) analogues by tethering the 6-OH of ring II and the 6‴-NH_2 of ring IV with a five-carbon bridge.[5b] However, the synthesized compounds were inactive at the concentrations lower than 40 μg/mL. Mobashery and van Delft also reported the syntheses of structurally constrained neamine (**1a**) derivatives, but no biological activity was reported.[5c,d]

Received: October 14, 2012
Published: December 10, 2012

 © 2012 American Chemical Society



Figure 1. Structures of representative aminoglycosides. The neamine core is composed of rings I and II.

The 3D structure of kanamycin A (**1d**) bound to the target ribosomal A-site RNA has been determined.[4l] In addition, several 3D structures of kanamycin A−enzyme complexes have been determined recently.[4] The 3D structures of the antibiotic in complex with the enzymes significantly differ from that observed in the kanamycin A/A-site RNA complex (Figure 2).



Figure 2. X-ray structures of kanamycin A bound to A-site (a), ANT4′ (b), or AAC2′ (c). Kanamycin A is shown as gray backbone. Atoms are colored by CPK. The 2′O-to-5O distances are indicated.

For instance, kanamycin A exists in a higher energy conformation when bound with ANT(4′)[4a] and AAC(2′),[4g] but it adopts the minimum energy conformation in the RNA-bound state. Therefore, it is possible to design analogues that can retain the ribosomal A-site RNA binding property but resist enzyme modifications.

Previous investigations demonstrated that neamine is the optimal pharmacophore to manifest the antibiotic activity.[6] The 3D structures of RNA−aminoglycoside complexes revealed that aminoglycosides bind to RNA in a similar fashion. The neamine sugar rings of different aminoglycosides adopt the same orientation, bind to relatively the same binding site, and have almost the same conserved contacts.[4i,l,m] In contrast, the other sugar segments of aminoglycosides looks disorderly. These observations suggest that neamine moiety might be a better target for modifications to gain unique antibacterial properties than other segments. In fact, modifications of ring III of neomycin B or ring IV of paromomycin led to significant decreases in affinity to 16S RNA in previous reports.[5a,b] We hope a direct restriction of the pseudodisaccharide of the neamine moiety can reduce the potentially negative impact on the affinity to 16S RNA while maintaining the conformational restriction. Moreover, electrostatic interaction is considered to be the main mode of aminoglycoside and RNA binding.[7] The ammonium positive ions play a major role in electrostatic interactions. Therefore, the modifications of the hydroxyl groups may be more likely than the modifications of the amino groups to generate active analogues. The crystal structure of kanamycin A in complex with ribosomal A-site RNA shows that both the 5-hydroxyl group of ring II and the 2′-hydroxyl group of ring I have no critical interaction with the RNA, and these two hydroxyl groups are proximate to each other (Figure 3). In



Figure 3. Crystal structure of kanamycin A−A site complex. Kanamycin A is shown as a green backbone. RNA is shown as a line. Atoms are colored by CPK. Hydrogen bonds between kanamycin A and RNA are shown with green dashed lines.

addition, the distances between O-5 and O-2′ of kanamycin A are different in the complexes with A-site, ANT(4′), or AAC(2′) (Figure 2). On the basis of these analyses, kanamycin A derivatives with their structures constrained by linking the 5-hydroxyl group of ring II and the 2′-hydroxyl group of ring I with carbon bridges were designed (compounds **2**−**5**, Figure 4). Different lengths (1−4 carbons) of the bridges were used to restrict the conformation of the kanamycin A at different degrees. Moreover, a double bond was introduced to enhance the conformational restriction (compound **6**). Because hydrogen-bonding interactions also play a key role in the binding of aminoglycosides with RNA, derivative **7** with protected hydroxyl groups was also prepared to evaluate the influence of the modifications of these two hydroxyl groups.

Synthesis. We prefer to use azido groups as the precursors of amines on kanamycin since the azido derivatives have excellent solubility in organic solvents. Tetraazidokanamycin A (**8**) was synthesized via a three-step procedure in 80% yield (Scheme 1). The commercially available kanamycin A (**1d**) was first converted into the perazido species by the modified diazo transfer procedure.[8] In order to facilitate the purification, the reaction residues were treated with acetic anhydride in pyridine to give peracetylated product. After purification by column chromatography, the peracetylated product was then deacetylated with NaOMe−MeOH to provide compound **8**. Our



Figure 4. Structures of designed kanamycin A analogues **2**−**7**.

synthesis required the selective protection of the hydroxyl groups of kanamycin A except for the 5-hydroxyl and 2′-hydroxyl groups. We previously isolated a byproduct 5,2′;4″,6″-di-*O*-benzylidene-protected tetraazidokanamycin A (**10**) during the synthesis of 4″,6″-*O*-benzylidene-protected tetraazidokanamycin A (**9**). Its structure was determined by the $^{1}H-^{1}H$ COSY, HMBC, HMQC, and DEPT of its acetylated derivative **10a** (Scheme 1).[9] The unique 5,2′-benzylidene group is an eight-membered structure that should be relatively unstable and could be selectively hydrolyzed. On the basis of these results, a three-step protection strategy was designed. Compound **8** was first treated with 2.4 equiv of benzaldehyde dimethyl acetal and a catalytic amount of *p*-toluenesulfonic acid under reduced pressure in DMF at 68 °C on a rotary evaporator for 12 h to furnish the desired product **10** in 46% yield. A further increase of the amount of benzaldehyde dimethyl acetal and the prolongation of reaction time did not improve the yield but was accompanied by the formation of byproducts. When acetonitrile was used as the solvent, compound **10** was afforded in 60% yield with the same proportion of the reactants as above reacted on a rotary evaporator at 40 °C for 5 min (Scheme 2). Compound **10** was then treated with NaH and benzyl bromide in DMF to afford the fully protected product **11**. We subsequently tested HCl (aq), acetic acid, or H_2SO_4 at different concentrations to selectively remove the 5,2′-*O*-benzylidene group, but they all failed to hydrolyze the 5,2′-*O*-benzylidene group selectively. It seems that this ring-cross benzylidene group was not as unstable as we previously assumed. Therefore, a two-step reaction was carried out. Complete hydrolysis of the two benzylidene groups with 0.004 M HCl (aq) at 50 °C for 3 h produced compound **12** in 93% yield, which was treated with 1.2 equiv of benzaldehyde dimethyl acetal in acetonitrile at room temperature for 3 h to afford the 4″, 6″-*O*-benzylidened product **13** in 75% yield.

The synthesis of compounds **2**−**5** involved the formation of 8-, 9-, 10-, and 11-membered intramolecular ether rings similar to crown ethers. Generally speaking, the preparations of medium sized crown ethers bearing 8−12 ring atoms often face considerable difficulties.[10,11] However, a dramatic increase of the yields could be obtained with the use of cesium carbonate as base in the synthesis of crown compounds.[10a] Treatment of compound **13** with dibromomethane in the presence of 8 equiv Cs_2CO_3 in DMF at 90 °C for 24 h afforded compound **14** with a methylene bridge in 67% yield (Scheme 2). However, when 1,2-dibromoethane was used to synthesize compound **15** with Cs_2CO_3 as the base, no product was observed even at higher temperature or longer reaction time. Similarly, 1,3-dibromopropane could not yield compound **16**. Stronger bases such as NaOH or NaH failed to promote these reactions. When compound **13** was treated with 1 equiv of 1,2-dimethylsulfonyloxyethane and 8 equiv of Cs_2CO_3 in DMF at 80 °C for 2 days, cyclic product **15** was prepared in 10% yield with the formation of 2′- or 5-*O*-sulfonate byproducts. When 3 equiv of 1,2-dimethylsulfonyloxyethane was used, the yield increased to 25%, but it was still not satisfactory. However, a further increase of the amount of 1,2-dimethylsulfonyloxyethane did not improve the yield. 1,2-Di-*p*-toluene sulfonyloxyethane (3 equiv) was then used, and the yield increased to 45%. As before, further increase of the amount of 1,2-di-*p*-toluene sulfonyloxyethane, reaction temperature, and reaction time did

Scheme 1. Synthesis of Compounds 10 and 10a[a]



[a]Conditions: (a) (i) Tf_2O, NaN_3, CH_3CN, 0 °C; (ii) $CuSO_4$, H_2O, CH_3CN, NEt_3, rt; (b) Ac_2O, pyridine, rt, yield 82% for two steps; (c) MeOH, MeONa, rt, 98%; (d) $PhCH(OCH_3)_2$, DMF, *p*-TsOH, 68 °C, 20% for **9**, 46% for **10**; (e) Ac_2O, pyridine, rt, 98%.

Scheme 2. Synthesis of the Cyclic Kanamycin A Derivatives 2−4[a]



[a]Conditions: (a) 2.4 equiv of $PhCH(OCH_3)_2$, p-TsOH, CH_3CN, 40 °C, 60%; (b) BnBr, DMF, NaH, rt, 95%; (c) THF, MeOH, HCl (aq), 50 °C, 93%; (d) 1.2 equiv of $PhCH(OCH_3)_2$, CH_3CN, p-TsOH, rt, 75%; (e) for **14**, Cs_2CO_3, DMF, CH_2Br_2, 90 °C, 24 h, 67%; for **15**, $TsOCH_2CH_2OTs$, Cs_2CO_3, DMF, 80 °C, 2 days, 45%; for **16**, $TsOCH_2CH_2CH_2OTs$, Cs_2CO_3, DMF, 80 °C, 2 days, 45%; (f) H_2S, Py, Et_3N, H_2O, 6 h; (g) HCl (aq), $Pd(OH)_2/C$, H_2, H_2O, 50−60% for two steps.

not improve the yield. Compared with previous reports of the similar reactions, the yield here would be satisfactory.[10−13] Similarly, treatment of compound **13** with 3 equiv of 1,3-di-p-toluenesulfonyloxypropane and 8 equiv of Cs_2CO_3 in DMF at 80 °C for 2 days afforded cyclic ether product **16** in 45% yield and 2′ or 5-O-allylated byproduct in 30% yield, while 1, 3-dimethylsulfonyloxypropane under the same conditions gave **16** in only 20% yield and 2′- or 5-O-allylated byproduct in 40% yield. We attempted to suppress this elimination reaction by using weaker base Na_2CO_3 or K_2CO_3, but no reaction was observed.

To construct the four-carbon bridge, a ring-closing metathesis reaction was employed. Allylic etherification of 5-hydroxyl and 2′-hydroxyl groups with NaH and ally bromide gave compound **17** in 90% yield (Scheme 3). Phosphine-free second-generation Hoveyda−Grubbs catalyst was applied for the ring-closure metathesis reaction because of the incompatibility of azido groups with the phosphine ligand of the second-generation Grubbs' catalyst.[5d] Treatment of compound **17** with 0.1 equiv catalyst in toluene for 24 h gave only *cis*-cyclic product **18** in 60% yield (J = 10.8 Hz). Increase of the amount of catalyst to 0.15 equiv and 0.2 equiv or elevation of temperature did not improve the yield significantly.

The deprotections of **14−16** and **18** were achieved by a two-step process because direct hydrogenation catalyzed by palladium carbon could not give a clean reaction.[8,9] At first, reduction of azido groups with hydrogen sulfide gas afforded the corresponding amines. After purification with column chromatography, debenzylation was then carried out by palladium carbon catalyzed hydrogenation under acidic conditions (pH = 3−4) to give final products **2−5** as hydrogen chloride salt (Schemes 2 and 3). These final products were purified by HPLC for biological activity test. To synthesize compound **6** with an unsaturated four-carbon bridge, boron trichloride[14] was tried to deprotect benzyl groups of compound **18** selectively. However, it did not give a clean reaction. Birch reduction[15] was tried subsequently, but the intramolecular allyl ether bond was decomposed (Scheme 3).[16]

To synthesize compound **6**, different protecting strategy has to be used. The p-methoxybenzyl protecting group was used because it could be deprotected by trifluoroacetic acid without affecting the allyl ether.[17] Treatment of 5,2′;4″,6″-O-benzylidenetetraazidokanamycin A (**10**) with p-methoxybenzyl chloride and NaH in DMF gave compound **19** in 93% yield, which was converted to **23** as shown in Scheme 4 as the synthesis of **18** from **11** in Scheme 3. After reduction of the azides to the corresponding amines with hydrogen sulfide gas, trifluoroacetic acid was then employed to remove PMB protective groups and benzylidene group to give compound **6** as the trifluoroacetate salt. Similarly, 5,2′-diallylkanamycin A (**7**) was also prepared from compound **22**. These two final products were purified by HPLC for biological activity tests.

Antibacterial Activity. The synthesized aminoglycosides **2−7** were assayed against susceptible bacterial strains, using kanamycin A as the control. Aminoglycoside-susceptible *Staphylococcus aureus* (ATCC 25923), *Staphylococcus epidermidis* (ATCC 12228), and *Escherichia coli* (ATCC 25922) were used. The minimum inhibitory concentrations (MICs) are

Scheme 3. Synthesis of the Cyclic Kanamycin A Derivative 5[a]



[a]Conditions: (a) NaH, DMF, allyl bromide, rt, 3h, 90%; (b) Hoveyda catalyst, toluene, rt, 24 h, 60%; (c) H_2S, Py, Et_3N, H_2O; (d) HCl (aq), $Pd(OH)_2/C$, H_2, H_2O, two-step yields: 60%.

Scheme 4. Synthesis of the Cyclic Kanamycin A Derivative 6 and 5,2′-Diallylkanamycin A (7)[a]



[a]Conditions: (a) PMBCl, NaH, DMF, rt, 6 h, 93%; (b) MeOH, THF, HCl, 60 °C, 90%; (c) $PhCH(OCH_3)_2$, CH_3CN, p-TsOH, rt, 70%; (d) NaH, DMF, allyl bromide, 90%; (e) Hoveyda catalyst, toluene, rt, 24 h, 50%; (f) H_2S, Et_3N, Py, H_2O, 6 h; (g) TFA, H_2O, rt, 2 h.

summarized in Table 1. All tested compounds showed decreased activity compared with kanamycin A. These results indicated that modifications of 5,2′-hydroxyl groups led to the decrease of activities against susceptible bacterial strains, as previously reported.[5a,b,18] However, conformational restrictions led to higher activity than simple alkylation of hydroxyl groups.

dx.doi.org/10.1021/jo302247x | J. Org. Chem. 2013, 78, 400−409

Table 1. MIC of the Synthesized Aminoglycosides against Susceptible Bacterial Strains and Resistant Bacterial Strains[a]

	S. aureus[b]	*S. epidermidis*[c]	*E. coli*[d]	*S. aureus*[e]	*K. pneumoniaeb*[f]	*E. coli*[g]
1d	4	4	4	16	32	16
2	8	8	8	>64	>64	32
3	16	16	16	32	32	16
4	64	64	>64	>64	>64	>64
5	32	32	32	>64	32	>64
6	16	16	32	32	32	32
7	32	32	64	>64	>64	64

[a]Unit: μg/mL. [b]*Staphylococcus aureus* (ATCC 25923). [c]*Staphylococcus epidermidis* (ATCC 12228). [d]*Escherichia coli* (ATCC 25922). [e]*Staphylococcus aureus* (ATCC 33591). [f]*Klebsiella pneumoniae* (ATCC 700603). [g]*Escherichia coli* (09-1).

In addition, antibacterial activities of these cyclic kanamycin A derivatives indeed varied with the length of the bridge. When the number of the carbon atoms in the bridges was less than or equal to three (derivatives **2**–**4**), the antibacterial activities of kanamycin A derivatives became weaker along with the extension of the carbon chain length. When the number of the carbon atoms in the bridges was four, derivative **6** with a double bond in the bridge showed better activity than derivative **5** with a saturated carbon chain, which showed similar activity as derivaive **7**. These results indicate the conformational recognition is important for the A site as a target.[19]

The activities of these synthesized aminoglycosides **2**–**7** against drug-resistant strains were then assayed. Clinically significant pathogens methicillin-resistant *S. aureus* (MRSA) (Gram-positive), *Klebsiella pneumoniae* (Gram-negative) and *Escherichia coli* (09–1) were used. Methicillin-resistant *S. aureus* (ATCC 33591) is the leading cause of bacterial infections, which express APH(3′), ANT(4′), and AAC(6′)/APH(2″) and render the bacteria resistant to various aminoglycosides.[20] *K. pneumoniae* (ATCC 700603) is resistant to several aminoglycosides (caused by ANT(2″).[21] *Escherichia coli* (09-1) is another clinical isolate obtained from patients in China in 2009.

The results are summarized in Table 1. As expected, the MIC of kanamycin A for the methicillin-resistant *S. aureus* (MRSA) is significantly increased compared with the susceptible *S. aureus* (ATCC 25923). Surprisingly, compound **2** showed 8-fold weaker activity against the methicillin-resistant *S. aureus* (MRSA) than the susceptible *S. aureus* (ATCC 25923). In contrast, the cyclic derivatives **3** and **6** showed only 2-fold less activity against *S. aureus* (MRSA) than against the nonresistant bacteria. In fact, compounds **3** and **6** showed better activity than compound **2** in all of the tested resistant bacterial strains. However, these two compounds did not show better activity than kanamycin A. These results indicated that conformational restrictions do not enhance the antibacterial activity of kanamycin A against the resistant bacterial strains. In fact, a similar result has been reported by Asensio and co-workers.[22]

■ CONCLUSION

We have designed and synthesized five conformationally constrained kanamycin A derivatives with modifications at the 5,2′-hydroxyl groups of the neamine core. After 5,2′-hydroxyl group exposed kanamycin A derivative was synthesized as the pivotal intermediate, cyclic kanamycin A derivatives with intramolecular 8,9,10,11-membered ethers were prepared by cesium carbonate mediated Williamson ether synthesis or ring-closing metathesis reaction. The antibacterial activities of these cyclic kanamycin A derivatives indeed varied with the lengths of the bridges. However, they did not show better antibacterial activities against tested resistant bacterial strains.

■ EXPERIMENTAL SECTION

1. Chemistry. ^{1}H and ^{13}C NMR spectra were recorded on 300 or 400 M instruments using TMS as the internal standard. High-resolution mass spectra (HRMS) were obtained in positive-ion electrospray ionization (ESI) mode using a TOF (time-of-flight) analyzer. Optical rotations were measured at 25 °C using a polarimeter. Column chromatography was performed on silica gel H60. Solvents were purified by standard procedures. The purification of the final products was carried out by HPLC (refractive index detector).

*1,3,6′,3″-Tetraazidokanamycin A (**8**).* To an ice-cooled suspension of NaN_3 (5.4 g, 83.08 mmol) in anhydrous CH_3CN (50 mL) was added trifluoromethanesulfonic anhydride (11.56 mL, 69.22 mmol) dropwise over 30 min, and the mixture was stirred for 2 h at 0 °C. The mixture was filtered quickly at 0 °C, and the filtrate was added slowly into a mixture of kanamycin A (5.82 g, 10 mmol), $CuSO_4$ (0.1 g, 0.6 mmol), triethylamine (9.08 mL), and H_2O (25 mL). The reaction was stirred for 24 h at room temperature. After completion of the reaction (monitored by TLC, acetone–EtOAc 1:1, v/v), the mixture was concentrated under reduced pressure to a green oil. To this green oil was added 100 mL of dried pyridine, followed by 20 mL of acetic anhydride. The mixture was stirred for 4 h at room temperature, and MeOH was added to quench the extra Ac_2O in ice bath. The solvent was removed at reduced pressure, and the remained mixture was precipitated by the addition of water to give a yellow solid. This crude product was purified with column chromatography (PE–EtOAc 5:1, v/v) to provide the product as colorless syrup (6.89 g, 8.2 mmol, 82%), R_f = 0.43 (PE–EtOAc 3:1, v/v). To a solution of the above product (840 mg, 1 mmol) in 50 mL of methanol was added sodium methoxide (about 1 M solution in methanol) dropwise to give a pH of 11. After completion of the reaction (in about 4 h, monitored by TLC, CH_2Cl_2–MeOH 3:1, v/v), the reaction was neutralized with cationic resin. The mixture was filtered and the filtrate concentrated under reduced pressure to give **8** (580 mg, 0.98 mmol, 98%) as an orange oil: R_f = 0.26 ($CHCl_3$–MeOH 3:1, v/v); $[\alpha]^{25}_D$ +80 (*c* 1.0, $CHCl_3$); ^{1}H NMR (300 MHz, DMSO-d_6) δ 5.32 (br s, 4H), 5.08 (d, 1H, *J* = 3.6 Hz), 5.06 (d, 1H, *J* = 3.6 Hz), 3.93 −3.82 (m, 2H), 3.69 (m, 1H), 3.56 − 3.06 (m, 14H), 2.28–2.24 (m, 1H), 1.59 −1.47 (m, 1H); ^{13}C NMR (75 MHz, DMSO-d_6) δ 100.9, 97.7, 83.3, 79.2, 73.9, 72.7, 72.0, 72.0, 71.8, 70.5, 70.3, 67.5, 67.1, 60.3, 59.7, 58.9, 51.4, 31.9; HR ESI MS calcd for $C_{18}H_{28}N_{12}NaO_{11}$ ([M + Na]$^+$) 611.1889, found 611.1893.

*1,3,6′,3″-Tetraazido-5,2′,4″,6″-di-O-benzylidenekanamycin A (**10**).* To a solution of compound **8** (5.88 g, 10 mmol) in dry CH_3CN (100 mL) was added *p*-toluenesulfonic acid monohydrate (50 mg), followed by benzaldehyde dimethyl acetal (3.6 mL, 24 mmol). The mixture was rotated under reduced pressure in CH_3CN at 40 °C on the rotary evaporator for 5 min. After completion of the reaction (monitored by TLC, CH_2Cl_2–MeOH 12:1, v/v), the reaction was quenched by addition of Et_3N (5 mL) and evaporated to dryness. The resulting crude product was purified with column chromatography (CH_2Cl_2–MeOH 50:1, v/v) to provide colorless foam **10** (4.58 g, 6.0 mmol, 60%): R_f = 0.56 (CH_2Cl_2–MeOH 12:1, v/v); $[\alpha]^{25}_D$ +92.8 (*c* 0.99, $CHCl_3$); ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.46–7.26 (m,10H), 5.99 (s, 1H), 5.49 (d, 1H, *J* = 3.9 Hz), 5.34(s, 1H), 5.17 (d, 1H, *J* = 3.6 Hz), 4.00 (t, 1H, *J* = 8.4 Hz), 3.87 – 3.23 (m, 15H), 2.90 (s, 1H), 2.29 (m, 1H),1.53 (m, 1H,); ^{13}C NMR (75 MHz, $CDCl_3$) δ 136.5, 134.6, 129.3, 129.1, 128.8, 128.1, 126.4, 126.0, 101.3, 101.0, 100.5, 99.0, 85.4, 81.1, 79.8,79.3, 73.1, 72.0, 71.9, 71.1, 69.2, 68.2, 63.9, 62.9, 59.6, 50.8, 31.5; HR ESI MS calcd for $C_{32}H_{37}N_{12}O_{11}$ ([M + H]$^+$) 765.2705, found 765.2708.

*1,3,6′,3″-Tetraazido-5,2′,4″,6″-di-O-benzylidene-3′,4′,2″-tri-O-benzylkanamycin A (**11**).* To a solution of **10** (764 mg, 1 mmol) in anhydrous DMF (30 mL) was added NaH (3 equiv) at 0 °C. After the

mixture was stirred for 5 min, BnBr (4.5 equiv) was added. Then the reaction mixture was warmed slowly to room temperature. After completion of the reaction (in about 6 h, monitored by TLC, PE–EtOAc 5:1, v/v), the reaction was quenched by addition of methanol. The reaction was concentrated under reduced pressure. The residue was dissolved in EtOAc, washed with brine, dried over Na_2SO_4, and concentrated under reduced pressure. The residue was purified by column chromatography (PE–EtOAc 10:1, v/v) to give compound **11** as yellow foam in 95% yield: R_f = 0.34 (PE–EtOAc 5:1, v/v); ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.43–7.10 (m, 25H), 6.02 (s, 1H), 5.45 (d, 1H, *J* = 4.2 Hz), 5.43 (d, 1H, *J* = 3.6 Hz), 5.25 (s, 1H), 5.00 (s, 1H), 5.00 (m, 1H), 4.83 (m, 4H), 4.50 (m, 1H), 4.10 (m, 4H), 3.87 (m, 4H), 3.66–3.57 (m, 5H), 3.46–3.22 (m, 6H), 3.19 (m, 1H), 2.25 (m, 1H), 1.50 (m, 1H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 138.6, 137.9, 137.1, 136.5, 134.8, 129.2, 128.9, 128.7, 128.4, 128.3, 128.2, 127.9, 127.8, 127.6, 126.4, 126.2, 101.3, 100.8, 99.1, 96.9, 85.5, 81.8, 79.3, 79.2, 78.2, 76.6, 75.6, 75.1, 73.5, 73.1, 70.5, 68.4, 63.1, 61.2, 60.3, 57.7, 50.8, 32.0; HR ESI MS calcd for $C_{53}H_{58}N_{13}O_{11}$ ([M + NH_4]$^+$) 1052.4367, found 1052.4373.

*1,3,6′,3″-Tetraazido-3′,4′,2″-tri-O-benzylkanamycin A (**12**).* To a solution of **11** (1.25g, 1.21 mmol) in THF–MeOH (2:1) (15 mL) was added 60 μL of 1 M HCl (aq). The reaction mixture was kept at 50 °C. After completion of the reaction (in about 3 h, monitored by TLC, CH_2Cl_2/MeOH = 10:1, v/v), the reaction was neutralized with anion resin. The mixture was filtered, and the filtrate was concentrated under reduced pressure, followed by chromatography (CH_2Cl_2/MeOH = 30:1), to give **12** (968 mg, 1.13 mmol, 93%) as colorless oil: $[\alpha]^{25}_D$ +130 (*c* 1.0, $CHCl_3$); ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.42–7.26 (m, 17H), 5.18–5.16 (m, 2H), 5.05 (d, *J* = 3.6 Hz, 1H), 4.92–4.79 (m, 4H), 4.67 (d, *J* = 11.6 Hz, 1H), 4.61 (d, *J* = 10.4 Hz, 1H), 4.17–4.95 (m, 3H), 3.84–3.46 (m, 8H), 3.39–3.21 (m, 6H), 2.32–2.29 (m, 1H), 155–1.46 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 138.4, 137.7, 137.1, 128.6, 128.6, 128.5, 128.2, 128.1, 128.1, 128.0, 127.9, 127.9, 127.7, 101.6, 96.9, 85.1, 82.1, 81.9, 78.1, 77.6, 77.2, 75.3, 75.2, 74.6, 72.9, 72.7, 71.5, 71.4, 69.4, 65.2, 62.2, 60.0, 51.1, 32.1; HR ESI MS calcd for $C_{39}H_{46}N_{12}NaO_{11}$ ([M + Na]$^+$) 881.3301, found 881.3289.

*1,3,6′,3″-Tetraazido-4″,6″-O-benzylidene-3′,4′,2″-tri-O-benzylkanamycin A (**13**).* To a solution of compound **12** (968 mg, 1.13 mmol) in dry CH_3CN (10 mL) was added *p*-toluenesulfonic acid monohydrate (10 mg, 0.05 mmol) followed by benzaldehyde dimethyl acetal (0.2 mL, 1.35 mmol, 1.2 equiv). The mixture was stirred at room temperature. After completion of the reaction (monitored by TLC, PE–EtOAc 2:1, v/v), the reaction was quenched by addition of Et_3N and evaporated to dryness. The resulting crude product was purified with column chromatography (PE–EtOAc 10:1, v/v) to provide colorless oil **13** (810 mg, 0.86 mmol, 75%): $[\alpha]^{25}_D$ +80 (*c* 1.0, $CHCl_3$); ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.52–7.25 (m, 20H), 5.53 (s, 1H), 5.17 (d, *J* = 3.6 Hz, 1H), 5.11 (d, *J* = 3.6 Hz, 1H), 4.94–4.77 (m, 5H), 4.65 (m, 1H), 4.25 (m, 2H), 4.04 (m, 2H), 3.82 (m, 1H), 3.65–3.23 (m, 12H), 2.19 (m, 1H), 1.63 (m, 1H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 138.1, 137.7, 137.1, 136.8, 129.0, 128.6, 128.5, 128.3, 128.2, 128.1, 128.0, 127.9, 126.0, 101.3, 97.6, 85.6, 81.8, 81.3, 79.7, 78.0, 77.4, 75.4, 75.1, 74.1, 73.3, 72.7, 71.4, 68.7, 63.0, 61.8, 60.0, 59.0, 51.1, 32.2; HR ESI MS calcd for $C_{46}H_{50}N_{12}O_{11}Na$ ([M + Na]$^+$) 969.3614, found 969.3612.

*1,3,6′,3″-Tetraazido- 4″,6″-O-benzylidene-3′,4′,2″-tri-O-benzyl-5,2′-O-methylenekanamycin A (**14**).* A mixture of **13** (190 mg, 0.2 mmol), dibromomethane (0.3 mL), and Cs_2CO_3 (0.5 g, 1.54 mmol) in anhydrous DMF (20 mL) was stirred at 90 °C for 24 h under argon. After being cooled to rt, the mixture was filtered and concentrated to dryness under reduced pressure. The residue was poured into H_2O (20 mL) and extracted with CH_2Cl_2 (3 × 10 mL). The combined organic phases were dried (Na_2SO_4), and the solvent was evaporated. The residue was purified with column chromatography (PE–EtOAc 10:1, v/v) to provide colorless oil **14** (128 mg, 0.13 mmol, 67%): ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.41–7.14 (m, 20H), 5.49 (d, *J* = 4.2 Hz, 1H), 5.43 (s, 1H), 5.34 (d, *J* = 3.9 Hz, 1H), 4.90–4.66 (m, 7H), 4.57–4.52 (m, 1H), 4.17–4.12 (m, 1H), 4.04–3.73 (m, 4H), 3.69–3.29 (m, 12H), 2.15 (m, 1H), 1.40 (m, 1H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 138.5, 137.9, 136.9, 136.7, 129.1, 128.5, 128.4, 128.3, 128.1, 127.8, 127.7, 127.6, 127.1, 126.9, 126.0, 101.5, 99.2, 96.7, 94.6, 84.8,81.9, 80.4, 79.3, 78.6, 77.7, 77.2, 76.6, 75.6, 75.1, 73.2, 70.8, 68.6, 63.0, 61.6, 60.3, 57.4, 50.7, 32.0; HR ESI MS calcd for $C_{47}H_{50}N_{12}O_{11}Na$ ([M + Na]$^+$) 981.3614, found 981.3614.

*1,3,6′,3″-Tetraazido-4″,6″-O-benzylidene-3′,4′,2″-tri-O-benzyl-5,2′-O-1,2-ethylkanamycin A (**15**).* A mixture of **13** (100 mg, 0.11 mmol), 1,2-di-*p*-toluenesulfonyloxyetane (122.1 mg, 3 equiv), and Cs_2CO_3 (275 mg, 0.845 mmol) in anhydrous DMF (20 mL) was stirred at 80 °C for 48 h under argon. After being cooled to rt, the mixture was filtered and concentrated to dryness under reduced pressure. The residue was poured into H_2O (20 mL) and extracted with CH_2Cl_2 (3 × 10 mL). The combined organic phases were dried (Na_2SO_4), and the solvent was evaporated. The residue was purified with column chromatography (PE–EtOAc 10:1, v/v) to provide colorless oil **15** (45 mg, 0.047 mmol, 45%): ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.45–7.25 (m, 21H), 5.59 (d, *J* = 3.2 Hz, 1H), 5.51 (s, 1H), 5.37 (d, *J* = 4.0 Hz, 1H), 4.93 (t, 2H), 4.82–4.76 (m, 3H), 4.62–4.59 (m, 1H), 4.14–4.02 (m, 2H), 4.02–3.95 (m, 2H), 3.86 (t, 1H), 3.71–3.64 (m, 2H), 3.56–3.31 (m, 12H), 2.38–2.34 (m, 1H), 1.60–1.50 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 138.0, 137.4, 137.0, 136.8, 129.7, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 127.5, 126.0, 101.6, 99.3, 96.0, 87.8, 83.0, 79.6, 77.9, 77.5, 77.3, 77.2, 75.3, 75.1, 73.2, 70.6, 68.8, 62.8, 61.5, 60.2, 58.6, 51.3, 32.2; HR ESI MS calcd for $C_{48}H_{52}N_{12}NaO_{11}$ ([M + Na]$^+$) 995.3771, found 995.3759.

*1,3,6′,3″-Tetraazido-4″,6″-O-benzylidene-3′,4′,2″-tri-O-benzyl-5,2′-O-1,3-propylkanamycin A (**16**).* A mixture of **13** (100 mg, 0.11 mmol), 1,3-di-*p*-toluenesulfonyloxypropane (126.7 mg, 3 equiv), and Cs_2CO_3 (275 mg, 0.845 mmol) in anhydrous DMF (20 mL) was stirred at 80 °C for 48 h under argon. After being cooled to rt, the mixture was filtered and concentrated to dryness under reduced pressure. The residue was poured into H_2O (20 mL) and extracted with CH_2Cl_2 (3 × 10 mL). The combined organic phases were dried (Na_2SO_4), and the solvent was evaporated. The residue was purified with column chromatography (PE–EtOAc 10:1, v/v) to provide colorless oil **15** (45 mg, 0.047 mmol, 45%): ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.44–7.26 (m, 24H), 5.52–5.50 (s, 2H), 5.20 (d, *J* = 3.3 Hz, 1H), 4.96–4.75 (m, 5H), 4.93 (t, 2H), 4.62–4.59 (m, 1H), 4.23–4.09 (m, 4H), 4.00–3.83 (m, 4H), 3.73–3.38 (m, 12H), 3.26–3.16 (m, 2H), 2.49–2.44 (m, 1H), 1.92–1.87 (m, 1H), 1.74–1.62 (m, 2H), 1.60–1.50 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 138.9, 136.9, 129.2, 128.5, 128.4, 128.3, 128.2, 127.9, 127.8, 127.5, 126.1, 101.9, 99.6, 96.3, 85.4, 82.7, 80.7, 79.6, 77.9, 77.3, 77.2, 75.2, 75.1, 73.2, 70.6, 62.8, 61.8, 61.5, 60.6, 60.4, 58.4, 51.3, 31.8, 28.8; HR ESI MS calcd for $C_{49}H_{54}N_{12}NaO_{11}$ ([M + Na]$^+$) 1009.3927, found 1009.3931.

*1,3,6′,3″-Tetraazido-4″,6″-O-benzylidene-3′,4′,2″-tri-O-benzyl-5,2′-di-O-allylkanamycin A (**17**).* To a solution of **13** (190 mg, 0.2 mmol) in anhydrous DMF (10 mL) was added NaH (3 equiv) at 0 °C. After the mixture was stirred for 5 min, allyl bromide (2 equiv) was added. Then reaction mixture was warmed slowly to room temperature. After completion of the reaction (monitored by TLC, PE–EtOAc 5:1, v/v), the reaction was quenched by addition of methanol. The mixture was poured into H_2O (20 mL) and extracted with CH_2Cl_2 (3 × 10 mL). The combined organic phases were dried (Na_2SO_4), and the solvent was evaporated. The residue was purified by column chromatography (PE–EtOAc 10:1, v/v) to afford **17** (185 mg, 0.18 mmol, 90%): $[\alpha]^{25}_D$ +60 (*c* 1.0, $CHCl_3$); ^{1}H NMR (300 MHz, $CDCl_3$) δ 7.48–7.24 (m, 20H), 5.96–5.81 (m, 2H), 5.60 (d, *J* = 3.6 Hz, 1H), 5.52 (d, *J* = 3.6 Hz, 1H), 5.47 (s, 1H), 5.34–5.08 (m, 2H), 4.93–4.74 (m, 6H), 4.63–4.50 (m, 2H), 3.70–3.33 (m, 11H), 2.41–2.36 (m, 1H), 1.67–1.55 (m, 1H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 138.4, 138.0, 137.1, 137.0, 134.2, 133.4, 129.0, 128.5, 128.4, 128.2, 127.8, 127.7, 126.2, 117.8, 116.5, 101.6, 99.1, 96.0, 82.3, 81.8, 79.7, 79.1, 78.3, 77.9, 77.4, 76.6, 75.6, 74.9, 73.9, 73.1, 70.6, 68.7, 62.5, 61.5, 60.2, 59.0, 51.2, 32.1; HR ESI MS Calcd for $C_{52}H_{62}N_{13}O_{11}$ ([M + NH_4]$^+$) 1044.4685, found 1044.4686.

*1,3,6′,3″-Tetraazido-4″,6″-O-benzylidene-3′,4′,2″-tri-O-benzyl-5,2′-O-(1,4-butyl-2-ene)kanamycin A (**18**).* Compound **17** (51 mg, 0.05 mmol) was coevaporated three times with toluene and dissolved in toluene (10 mL) again. Argon was bubbled through the solution for 10 min. To the reaction mixture was added Hoveyda–Grubbs catalyst

dx.doi.org/10.1021/jo302247x | J. Org. Chem. 2013, 78, 400–409

(0.1 equiv). The mixture was stirred at room temperature. After the reaction was complete (approximately after 24 h, monitored by TLC), the mixture was treated with DMSO (50 equiv, relative to catalyst) overnight. The solution was concentrated in vacuo and purified by column chromatography (PE−EtOAc 8:1, v/v) to provide the RCM product **18** (29.9 mg, 0.03 mmol, 60%) asa colorless oil: $[\alpha]^{25}{}_{D}$ +84 (*c* 1.0, $CHCl_3$); ^1H NMR (400 MHz, $CDCl_3$) δ 7.46−7.25 (m, 2H), 5.99−5.92 (m, 1H), 5.72−5.67 (m, 1H), 5.58 (d, *J* = 4.4 Hz, 1H), 5.51 (s, 1H), 5.49 (d, *J* = 3.6 Hz, 1H), 5.11 (dd, J_1 = 9.6 Hz, J_2 = 11.2 Hz, 1H), 4.95−4.75 (m, 5H), 4.65−4.60 (m, 2H), 4.32−4.18 (m, 4H), 4.13−4.08 (m, 1H), 3.98 (t, 1H), 3.87 (t, 1H), 3.69−3.57 (m, 2H), 3.51−3.36 (m, 10H), 2.46−2.40 (m, 1H), 1.64 (dd, J_1 = 12.4 Hz, J_2 = 24.8 Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ 138.6, 138.0, 137.0, 136.9, 130.6, 130.0, 129.1, 128.6, 128.5, 128.4, 128.4, 128.2, 128.0, 127.9, 127.8, 127.7, 126.2, 101.8, 99.2, 96.5, 82.7, 82.3, 82.0, 78.1, 77.7, 77.3, 77.2, 76.0, 75.8, 75.1, 73.2, 70.5, 70.3, 68.7, 62.7, 61.8, 60.8, 60.4, 58.3, 51.2, 32.0; HR ESI MS calcd for $C_{50}H_{58}N_{13}O_{11}$ ($[M + NH_4]^+$) 1016.4413, found 1016.4373.

*5, 2′-O-Methylenekanamycin A (**2**).* Compound **14** (96 mg, 0.1 mmol) was dissolved in Et_3N−pyridine−H_2O (3:2:1), and H_2S gas was bubbled into the solution for 1 h. The mixture was stirred for another 5 h. The solvent was removed under reduced pressure, followed by column chromatography ($CHCl_3$/MeOH/NH_4OH = 20:1:0.5), to provide benzylated kanamycin A as a colorless oil. The benzylated kanamycin A was added with catalytic amount of $Pd(OH)_2$/C and 5 mL of CH_3OH (pH = 3−4). The reaction mixture was stirred at room temperature under hydrogen of 5 atm for 2 day. Then the mixture was filtered through Celite. The residue was washed with water, and the combined solutions were concentrated affording crude product as a HCl salt in 54% yield. The product was purified by HPLC (0.025 M CF_3COOH in H_2O and CH_3OH (19:1)) to afford compound **2** as a salt of trifluoroacetic acid: ^1H NMR (300 MHz, D_2O) δ 5.56 (s, 1H), 4.95 (s, 1H), 4.84 (s, 2H), 3.85−2.93 (m, 16H), 2.38 (m, 1H), 1.83−1.53 (m, 1H); ^{13}C NMR (75 MHz, D_2O) δ 101.9, 99.1, 95.5, 82.3, 80.5, 99.6, 78.8, 73.7, 72.5, 70.7, 68.9, 65.7, 60.2, 55.3, 50.5, 48.3, 40.9, 28.4; HR ESI MS calcd for $C_{19}H_{37}N_4O_{11}$ ($[M + H]^+$) 497.2453, found 497.2440.

*5, 2′-O-1,2-Ethylkanamycin A (**3**).* Compound **3** was prepared in a way similar to that for **2**: yield 52% for two steps; ^1H NMR (400 MHz, D_2O) δ 5.50 (d, *J* = 3.6 Hz, 1H), 5.08 (d, *J* = 3.2 Hz, 1H), 4.31−4.29 (m, 1H), 4.02−3.95 (m, 2H), 3.99−3.89 (m, 3H), 3.85−3.32 (m, 17H), 3.25 (t, *J* = 10.0 Hz, 1H), 3.04 (dd, J_1 = 8.4 Hz, J_2 = 13.6 Hz, 1H), 2.46−2.43 (m, 1H), 1.88 (dd, J_1 = 12.4 Hz, J_2 = 25.2 Hz, 1H); ^{13}C NMR (100 MHz, D_2O) δ 101.7, 98.5, 88.3, 83.5, 80.5, 80.0, 71.2, 70.5, 68.5, 68.4, 65.0, 59.4, 54.6, 49.7, 47.8, 27.9; HR ESI MS calcd for $C_{20}H_{39}N_4O_{11}$ ($[M + H]^+$) 511.2610, found 511.2610.

*5, 2′-O-1,3-Propylkanamycin A (**4**).* Compound **4** was prepared in a way similar to that for **2**: yield 59% for two steps; ^1H NMR (400 MHz, D_2O) δ 5.50 (d, *J* = 2.4 Hz, 1H), 5.14 (d, *J* = 2.4 Hz, 1H), 4.18−4.16 (m, 1H), 4.05−4.03 (m, 1H), 3.96−3.29 (m, 22H), 3.18−3.15 (m, 1H), 2.58−2.55 (m, 1H), 1.98−1.74 (m, 1H); ^{13}C NMR (100 MHz, D_2O) δ 101.6, 99.8, 83.4, 83.0, 82.5, 77.2, 73.2, 71.1, 70.5, 70.2, 68.4, 68.3, 59.5, 54.6, 49.9, 48.2, 46.7, 39.8, 28.2, 27.8; HR ESI MS calcd for $C_{21}H_{41}N_4O_{11}$ ($[M + H]^+$) 525.2766, found 525.2760.

*5, 2′-O-1,4-Butylkanamycin A (**5**).* Compound **5** was prepared in a way similar to that for **2**: yield 55% for two steps; ^1H NMR (400 MHz, D_2O) δ 5.50 (d, *J* = 3.2 Hz, 1H), 5.07 (d, *J* = 2.0 Hz, 1H), 3.93−3.63 (m, 16H), 3.55−3.33 (m, 8H), 3.21−3.17 (m, 1H), 2.47 (d, *J* = 12.0 Hz, 1H), 1.92−1.75 (m, 4H), 1.56−1.44 (m, 1H); ^{13}C NMR (100 MHz, D_2O) δ101.9, 101.2, 83.2, 82.8, 79.6, 78.2, 75.5, 73.8, 73.3, 70.9, 70.8, 68.6, 68.5, 64.8, 59.1, 54.6, 49.9, 48.2, 40.2, 28.4, 28.1, 24.1; HR ESI MS calcd for $C_{22}H_{43}N_4O_{11}$ ($[M + H]^+$) 539.2923, found 539.2922.

*1,3,6′,3″-Tetraazido-5,2′,4″,6″-di-O-benzylidene-3′,4′,2″-tri-O-p-methoxybenzylkanamycin A (**19**).* To a solution of **10** (2.5g, 3.27 mmol) in anhydrous DMF (30 mL) was added NaH (3 equiv) at 0 °C. After the mixture was stirred for 5 min, *p*-methoxybenzyl chloride (4.5 equiv) was added. Then reaction mixture was warmed slowly to room temperature. After completion of the reaction (monitored by TLC, PE−EtOAc 3:1, v/v), the reaction was quenched by addition of methanol. The mixture was poured into H_2O (20 mL) and extracted with CH_2Cl_2 (3 × 10 mL). The combined organic phases were dried (Na_2SO_4), and the solvent was evaporated. The residue was purified by column chromatography (PE−EtOAc 10:1, v/v) to afford **19** (3.42g, 3.04 mmol, 93%): ^1H NMR (400 MHz, $CDCl_3$) δ 7.44−7.25 (m, 15H), 7.19−7.13 (m, 4H), 6.93−6.86 (m, 7H), 6.06 (s, 1H), 5.47 (d, *J* = 4.8 Hz, 1H), 5.45 (d, *J* = 3.2 Hz, 1H), 5.27 (s, 1H), 4.94 (d, *J* = 10.8 Hz, 1H), 4.78−4.70 (m, 4H), 4.46 (d, *J* = 10.8 Hz, 1H), 4.18−4.11 (m, 2H), 3.91−3.78 (m, 14H), 3.74−3.60 (m, 6H), 3.51−3.46 (m, 1H), 3.41−3.31 (m, 5H), 3.21 (t, *J* = 10.0 Hz, 1H), 2.32−2.29 (m, 1H), 1.61 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 159.7, 159.3, 136.6, 135.5, 134.9, 130.9, 130.2, 130.0, 129.6, 129.5, 129.2, 129.1, 128.9, 128.7, 127.9, 126.5, 126.3, 113.9, 113.8, 113.7, 101.3, 100.8, 99.1, 96.9, 85.5, 81.8, 79.3, 79.2, 78.2, 77.8, 77.2, 76.5, 75.6, 75.3, 74.8, 73.2, 70.5, 68.4, 63.1, 61.2, 60.3, 57.7, 55.3(2), 50.8, 32.1; HR ESI MS calcd for $C_{56}H_{60}N_{12}NaO_{14}$ ($[M + Na]^+$) 1147.4244, found 1147.4227.

*1,3,6′,3″-Tetraazido-4″,6″-O-benzylidene-3′,4′,2″-tri-O-p-methoxybenzylkanamycin A (**21**).* To a solution of **19** (0.625 g, 0.56 mmol) in THF−MeOH (2:1) (7.5 mL) was added 30 μL of 1 M HCl (aq). The reaction mixture was kept at 50 °C. After completion of the reaction (in about 3 h, monitored by TLC, CH_2Cl_2/MeOH = 10:1, v/v), the reaction was neutralized with cationic resin. The mixture was filtered, and the filtrate was concentrated under reduced pressure, followed by chromatography (CH_2Cl_2/MeOH = 30:1) to give **20** (477 mg, 90%) as a colorless oil. To a solution of compound **20** (477 mg, 0.5 mmol) in dry CH_3CN (10 mL) was added *p*-toluenesulfonic acid monohydrate (10 mg, 0.05 mmol) followed by benzaldehyde dimethyl acetal (0.09 mL, 0.6 mmol, 1.2eq). The mixture was stirred at room temperature. After completion of the reaction (monitored by TLC, PE−EtOAc 2:1, v/v), the reaction was quenched by addition of Et_3N and evaporated to dryness. The resulting crude product was purified with column chromatography (PE−EtOAc 10:1, v/v) to provide colorless oil **21** (362 mg, 0.35 mmol, 70%): yield for two steps 63%; ^1H NMR (400 MHz, $CDCl_3$) δ 7.51−7.49 (m, 2H), 7.40−7.34 (m, 5H), 7.29−7.22 (m, 7H), 6.92−6.86 (m, 6H), 5.53 (s, 1H), 5.13 (m, 2H), 4.88−4.79 (m, 2H), 4.76−4.70 (m, 2H), 4.66 (d, *J* = 1.6 Hz, 1H), 4.56 (d, *J* = 10.8 Hz, 1H), 4.26−4.23 (m, 1H), 4.10−3.99 (m, 2H), 3.81−3.79 (m, 7H), 3.77 (s, 1H), 3.72−3.63 (m, 2H), 3.59−3.48 (m, 5H), 3.44−3.38 (m, 3H), 3.33 (t, *J* = 10.4 Hz, 1H), 3.29−3.26 (m, 2H), 2.94 (d, *J* = 4.4 Hz, 1H), 2.41−2.38 (m, 1H), 1.61 (t, *J* = 5.6 Hz, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 159.6, 159.5, 159.4, 136.7, 135.5, 134.9, 130.4, 130.0, 129.6, 129.5, 129.2, 129.1, 128.3, 126.0, 114.0, 113.9, 113.8, 101.4, 101.3, 97.6, 85.5, 81.8, 81.3, 79.7, 77.8, 77.6, 77.2, 75.1, 74.8, 74.2, 73.0, 72.8, 71.4, 68.8, 63.1, 61.8, 60.0, 59.0, 55.3, 51.1, 32.3; HR ESI MS calcd for $C_{49}H_{56}N_{12}NaO_{14}$ ($[M + Na]^+$) 1059.3931, found 1059.3930.

*1,3,6′,3″-Tetraazido-4″,6″-O-benzylidene-3′,4′,2″-tri-O-p-methoxybenzyl-5,2′-di-O-allylkanamycin A (**22**).* Compound **22** was prepared in a way similar to that for **17**: yield 90%; ^1H NMR (400 MHz, $CDCl_3$) δ 7.47−7.44 (m, 2H), 7.38−7.33 (m, 5H), 7.26 (t, *J* = 4.8 Hz, 1H), 7.21 (d, *J* = 8.4 Hz, 1H), 6.91 (d, *J* = 8.4 Hz, 1H), 6.88−6.84 (m, 4H), 5.93−5.85 (m, 2H), 5.55 (d, *J* = 3.6 Hz, 1H), 5.50 (d, *J* = 3.6 Hz, 1H), 5.47 (s, 1H), 5.32−5.22 (m, 2H), 5.16 (dd, J_1 = 1.2 Hz, J_2 = 10.4 Hz, 1H), 5.09 (dd, J_1 = 1.2 Hz, J_2 = 10.8 Hz, 1H), 4.85−4.75 (m, 4H), 4.69 (d, *J* = 11.2 Hz, 1H), 4.55−4.49 (m, 2H), 4.34−4.30 (m, 2H), 4.26−4.05 (m, 5H), 3.82−3.79 (m, 9H), 3.66−3.31 (m, 13H), 2.41−2.37 (m, 1H), 1.66−1.58 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 159.6, 159.3, 159.2, 137.1, 134.4, 133.5, 130.7, 130.2, 129.9, 129.5, 129.5, 129.2, 129.0, 128.0, 126.2, 117.7, 116.5, 114.0, 113.8, 101.7, 97.2, 96.2, 82.3, 81.7, 79.8, 79.2, 78.0, 77.5, 77.2, 76.9, 76.6, 75.3, 74.6, 73.9, 72.8, 70.7, 68.8, 62.5, 61.5, 60.3, 59.1, 55.3, 51.3, 32.2; HR ESI MS calcd for $C_{55}H_{64}N_{12}NaO_{14}$ ($[M + Na]^+$) 1139.4557, found 1139.4561.

*1,3,6′,3″-Tetraazido-4″,6″-O-benzylidene-3′,4′,2″-tri-O-p-methoxybenzyl-5,2′-O-(1,4 butyl-2-ene)kanamycin A (**23**).* Compound **23** was prepared in a way similar to that for **18**: yield 50%, only *cis*-product was detected; ^1H NMR (400 MHz, $CDCl_3$) δ 7.47−7.44 (m, 4H), 7.36−7.34 (m, 5H), 7.30−7.26 (m, 8H), 7.22 (d, *J* = 8.8 Hz, 2H), 6.92−6.86 (m, 6H), 5.98−5.93 (m, 1H), 5.72−5.68 (m, 1H), 5.56 (d, *J* = 4.4 Hz, 1H), 5.51 (s, 1H), 5.45 (d, *J* = 3.6 Hz, 1H), 5.11 (t, *J* = 10.2 Hz, 1H), 4.87−4.76 (m,4H), 4.69 (d, *J* = 11.2 Hz, 1H), 4.54

(d, J = 10.8 Hz, 1H), 4.33−4.08 (m, 5H), 3.96 (t, J = 9.6 Hz, 1H), 3.85−3.78 (m, 10H), 3.69−3.33 (m, 11H), 2.46−2.41 (m, 1H), 1.64 (dd, J_1 = 12.4 Hz, J_2 = 25.6 Hz, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 159.7, 159.4, 159.3, 137.0, 130.8, 130.6, 130.2, 130.1, 130.0, 129.7, 129.6, 129.5, 129.1, 128.9, 128.3, 126.2, 114.0, 113.9, 113.8, 101.8, 99.2, 96.6, 82.7, 82.3, 82.0, 80.1, 79.6, 77.8, 75.5, 74.7, 72.8, 70.5, 70.3, 70.2, 68.7, 62.7, 61.8, 60.6, 58.3, 55.3, 51.2, 32.0; HR ESI MS calcd for $C_{53}H_{60}N_{12}NaO_{14}$ ([M + Na]$^+$) 1111.4244, found 1111.4246.

*5, 2′-O-(1,4-Butyl-2-ene)kanamycin A (**6**).* Compound **23** (100 mg, 0.09 mmol) was dissolved in NEt_3−pyridine−H_2O (3:2:1), and H_2S gas was bubbled into the solution for 1 h. The mixture was stirred for another 5 h. The solvent was removed under reduced pressure, followed by column chromatography ($CHCl_3$/MeOH/NH_4OH = 20:1:0.5) provided *p*-methoxybenzylated kanamycin A as a colorless oil. To the solution of *p*-methoxybenzylated kanamycin A in H_2O (1 mL) was added 0.5 mL of trifluoroacetice acid. The mixture was stirred for 2 h. The solvent was removed under reduced pressure, followed by column chromatography (ODS, water) to give the crude product in 53% yield. The product was purified by HPLC (0.025 M CF_3COOH in H_2O and CH_3OH 19:1) to afford compound **6** as a salt of trifluoroacetic acid: ^{1}H NMR (400 MHz, D_2O) δ 5.87−5.80 (m, 2H), 5.64 (d, J = 4.0 Hz, 1H), 5.04 (d, J = 2.4 Hz, 1H), 4.47 (d, J = 15.2 Hz, 1H), 4.30 (dd, J_1 = 4.4 Hz, J_2 = 9.2 Hz, 1H), 4.02 (dd, J_1 = 5.2 Hz, J_2 = 15.2 Hz, 1H), 3.50−3.25 (m, 7H), 2.93 (dd, J_1 = 7.2 Hz, J_2 = 14.4 Hz, 1H), 2.41 (dd, J_1 = 4.4 Hz, J_2 = 8.0 Hz, 1H), 1.91 (dd, J_1 = 12.4 Hz, J_2 = 25.2 Hz, 1H); ^{13}C NMR (100 MHz, D_2O) δ 131.6, 129.6, 101.7, 99.0, 83.5, 82.8, 79.6, 77.4, 73.2, 71.2, 71.1, 70.6, 68.8, 68.5, 65.0, 59.5, 54.6, 50.0, 48.1, 40.3, 28.2; HR ESI MS calcd for $C_{22}H_{41}N_4O_{11}$ ([M + H]$^+$) 537.2766, found 537.2766.

*5,2′-Di-O-allylkanamycin A (**7**).* Compound **7** was prepared in a way similar to that for **6**: yield 68%; ^{1}H NMR (400 MHz, D_2O) δ 5.94−5.79 (m, 2H), 5.56 (d, J = 2.4 Hz, 1H), 5.28−5.14 (m, 4H), 5.07 (d, J = 2.4 Hz, 1H), 4.30−4.20 (m, 4H), 4.11 (dd, J_1 = 6.4 Hz, J_2 = 12.0 Hz, 1H), 4.03 (t, J = 9.6 Hz, 1H), 3.90 (t, J = 9.6 Hz, 1H), 3.84−3.63 (m, 9H), 3.49−3.26 (m, 6H), 3.09 (dd, J_1 = 8.0 Hz, J_2 = 13.6 Hz, 1H), 2.41−2.38 (m, 1H), 1.93 (dd, J_1 = 12.0 Hz, J_2 = 25.2 Hz, 1H); ^{13}C NMR (100 MHz, D_2O) δ 133.5, 133.5, 119.4, 118.2, 101.1, 95.2, 81.5, 81.4, 77.9, 73.8, 73.6, 73.0, 71.4, 71.3, 71.2, 68.8, 68.5, 64.9, 59.2, 54.6, 49.9, 48.4, 40.4, 27.7; HR ESI MS calcd for $C_{24}H_{45}N_4O_{11}$ ([M + H]$^+$) 565.3079, found 565.3084.

2. Antibacterial Assay. Minimum inhibitory concentrations (MIC) (μg/mL) were determined by the microdilution broth method according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Inoculum was prepared by diluting actively growing broth cultures to a McFarland value of 0.5 (1−108 cfu/mL). Antibiotic dilutions were made by dispensing 0.1 mL into each of the 96 wells of a standard microtiter tray in 2-fold dilutions. The inoculum was added to give a final concentration of 0.03−64 μg/mL. The trays were covered and incubated at 35 °C for 16−20 h. The MIC was defined as the lowest concentration of drug inhibiting visible growth. The microdilution broth susceptibility testing was performed in triplicate.

■ ASSOCIATED CONTENT

Ⓢ Supporting Information

Copies of ^{1}H and ^{13}C NMR spectra of compounds **2−7**, **11−19**, and **21−23**. This material is available free of charge via the Internet at http://pubs.acs.org.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: 86 10 82801714. E-mail: (X.M.) xbmeng@bjmu.edu.cn, (Z.L.) zjli@bjmu.edu.cn.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was financially supported by the National Basic Research Program of China (Grant No. 2012CB822100) and the Ministry of Science and Technology of China (2012ZX09502001-001).

■ REFERENCES

(1) For reviews, see: (a) Kotra, L. P.; Haddad, J.; Mobashery, S. *Antimicrob. Agents Chemother.* **2000**, *44*, 3249. (b) Magnet, S.; Blanchard, J. S. *Chem. Rev.* **2005**, *105*, 477.

(2) For examples, see: (a) Roestamadji, J.; Grapsas, I.; Mobashery, S. *J. Am. Chem. Soc.* **1995**, *117*, 80. (b) Haddad, J.; Vakulenko, S. B.; Mobashery, S. *J. Am. Chem. Soc.* **1999**, *121*, 11922. (c) Kim, C.; Haddad, J.; Vakulenko, S. B.; Meroueh, S. O.; Wu, Y.; Yan, H.; Mobashery, S. *Biochemistry* **2004**, *43*, 2373. (d) Gao, F.; Yan, X.; Baettig, O. M.; Berghuis, A. M.; Auclair, K. *Angew. Chem., Int. Ed.* **2005**, *44*, 6859. (e) Magalhaes, M. L. B.; Vetting, M. W.; Gao, F.; Freiburger, L.; Auclair, K.; Blanchard, J. S. *Biochemistry* **2008**, *47*, 579.

(3) (a) Li, J.; Chang, C.-W. T. *Anti-Infective Agents in Medicinal Chemistry* **2006**, *5*, 255−271. (b) Hanessian, S.; Szychowski, J.; Adhikari, S. S.; Vasquez, G.; Kandasamy, P.; Swayze, E. E.; Migawa, M. T.; Ranken, R.; François, B.; Wirmer-Bartoschek, J.; Kondo, J.; Westhof, E. *J. Med. Chem.* **2007**, *50*, 2352. (c) Zhang, J.-J.; Chiang, F.-I.; Wu, L.; Czyryca, P. G.; Li, D.; Chang, C.-W. T. *J. Med. Chem.* **2008**, *51*, 7563. (d) Bera, S.; Zhanel, G. G.; Schweizer, F. *J. Med. Chem.* **2008**, *51*, 6160. (e) Pokrovskaya, V.; Belakhov, V.; Hainrichson, M.; Yaron, S.; Baasov, T. *J. Med. Chem.* **2009**, *52*, 2243. (f) Bera, S.; Zhanel, G. G.; Schweizer, F. *J. Med. Chem.* **2010**, *53*, 3626. (g) Hanessian, S.; Pachamuthu, K.; Szychowski, J.; Giguere, A.; Swayze, E. E.; Migawa, M. T.; Francois, B.; Kondo, J.; Westhof, E. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 7097. (h) Vacas, T.; Corzana, F.; Jimenez-Oses, G.; Gonzalez, C.; Gomez, A. M.; Bastida, A.; Revuelta, J.; Asensio, J. L. *J. Am. Chem. Soc.* **2010**, *132*, 12074. (i) Yang, L.; Ye, X.-S. *Curr. Med. Chem.* **2010**, *10*, 1898. (j) Yan, R.-B.; Yuan, M.; Wu, Y.-F.; You, X.-F.; Ye, X.-S. *Bioorg. Med. Chem.* **2011**, *19*, 30. (k) Shaul, P.; Green, K. D.; Rutenberg, R.; Kramer, M.; Berkov-Zrihen, Y.; Breiner-Goldstein, E.; Garneau- Tsodikova, S.; Fridman, M. *Org. Biomol. Chem.* **2011**, *11*, 4057. (l) Szychowski, J.; Kondo, J.; Zahr, O.; Auclair, K.; Westhof, E.; Hanessian, S.; Keillor, J. W. *ChemMedChem* **2011**, *6*, 1961. (m) Vong, K.; Auclair, K. *ChemMedChem* **2012**, *3*, 397.

(4) (a) Pedersen, L. C.; Benning, M. M.; Holden, H. M. *Biochemistry* **1995**, *34*, 13305. (b) Fourmy, D.; Recht, M. I.; Blanchard, A. C.; Puglisi, J. D. *Science* **1996**, *274*, 1367. (c) Yoshizawa, S.; Fourmy, D.; Puglisi, J. D. *EMBO J.* **1998**, *17* (22), 6437. (d) Carter, A. P.; Clemons, W. M.; Brodersen, D. E.; Morgan-Warren, R. J.; Wimberly, B. T.; Ramakrishnan, V. *Nature* **2000**, *407*, 340. (e) Vicens, Q.; Westhof, E. *Structure* **2001**, *9*, 647. (f) Fong, D. H.; Berghuis, A. M. S. *EMBO J.* **2002**, *21*, 2323. (g) Vetting, M. W.; Hegde, S. S.; Javid-Majd, F.; Blanchard, J. S.; Roderick, S. L. *Nat. Struct. Biol.* **2002**, *9*, 653. (h) Vicens, Q.; Westhof, E. *Chem. Biol.* **2002**, *9*, 747. (i) Vicens, Q.; Westhof, E. *Biopolymers* **2003**, *70*, 42. (j) Nurizzo, D.; Hewry, S. C.; Erlin, M. H.; Brown, S. A.; Holakia, J. N.; Fuchs, R. L.; Eva, T.; Baker, E. N.; Smith, C. A. *J. Mol. Biol.* **2003**, *21*, 491. (k) Lynch, S. R.; Gonzalez, R. L., Jr.; Puglisi, J. D. *Structure* **2003**, *11*, 43. (l) Francois, B.; Westhof., E. *Nucleic Acids Res.* **2005**, *33*, 5677. (m) Han, Q.; Zhao, Q.; Fish, S.; Simonsen, K. B.; Vourloumis, D.; Froelich, J. M.; Wall, D.; Hermann, T. *Angew. Chem., Int. Ed.* **2005**, *44*, 2694. (n) Maurice1, F.; Broutin, I.; Podglajen, I.; Benas, P.; Collatz, E.; Dardel, F. *EMBO Rep.* **2008**, *9*, 344−349. (o) Vetting, M. W.; Park, C. H.; Hedge, S. S.; Jacoby, G. A.; Hooper, D. C.; Blanchard, J. S. *Biochemistry* **2008**, *47*, 9825−9835. (p) Shi, K.; Houston, D. R.; Berghuis, A. M. *Biochemistry* **2011**, *50*, 6237−6244. (q) Shakya, T.; Stogios, P. J.; Waglechner, N.; Evdokimova, E.; Ejim, L.; Blanchard, J. E.; McArthur, A. G.; Savchenko, A.; Wright, G. D. *Chem.Biol.* **2011**, *18*, 1591−1601.

(5) (a) Bastida, A.; Hidalgo, A.; Chiara, J. L.; Torrado, M.; Corzana, F.; Pérez-Canadillas, J. M.; Groves, P.; Garcia-Junceda, E.; Gonzalez, C.; Jimenez-Barbero, J.; Asensio, J. L. *J. Am. Chem. Soc.* **2006**, *128*, 100. (b) Hanessian, S.; Szychowski, J.; Pineda, N. B. C.-R.; Furtos, A.;

Keillor, J. W. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 322. (c) Kling, D.; Hesek, D.; Shi, Q.-C.; Mobashery, S. *J. Org. Chem.* **2007**, *72*, 5450. (d) Busscher, G. F.; van den Broek, S. A. M. W.; Rutjes, F. P. J. T.; van Delft, F. L. *Tetrahedron* **2007**, *63*, 3183.

(6) (a) Greenberg, W. A.; Priestley, E. S.; Sears, P. S.; Alper, P. B.; Rosenbohm, C.; Hendrix, M.; Hung, S.-C.; Wong, C.-H. *J. Am. Chem. Soc.* **1999**, *121*, 6527. (b) Vourloumis, D.; Takahashi, M.; Winters, G. C.; Simonsen, K. B.; Ayida, B. K.; Barluenga, S.; Qamar, S.; Shandrick, S.; Zhao, Q.; Hermann, T. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 3367. (c) Venot, A.; Swayze, E. E.; Griffey, R. H.; Boons, G.-J. *ChemBioChem* **2004**, *5*, 1228. (d) Pang, L.-J.; Wang, D.; Zhou, J.; Zhang, L.-H.; Ye, X.-S. *Org. Biomol. Chem.* **2009**, *7*, 4252.

(7) Wang, H.; Tor, Y. *J. Am. Chem. Soc.* **1997**, *119*, 8734.

(8) Yan, R.-B.; Yang, F.; Wu, Y.-F.; Zhang, L.-H.; Ye, X.-S. *Tetrahedron Lett.* **2005**, *46*, 8993.

(9) Chen, Y.; Meng, X.-B.; Chen, G.-H.; Pan, P.; Li, Z.-J. *J. Chin. Pharm. Sci.* **2008**, *17*, 138.

(10) (a) Ostrowicki, A.; Koepp, E.; Vögtle, F. *Top. Curr. Chem.* **1992**, *161*, 39. (b) Parker., D. *Macrocycle Synthesis: a Practical Approach*: Oxford University Press: Oxford, 1996; pp 77−91.

(11) (a) De Voss, J. J.; Sui, Z.-H. *Tetrahedron Lett.* **1994**, *35* (1), 49. (b) Ghosh, A. K.; Gemma, S.; Baldridge, A.; Wang, Y.-F.; Kovalevsky, A. Y.; Koh, Y.; Weber, I. T.; Mitsuya, H. *J. Med. Chem.* **2008**, *51*, 6021.

(12) (a) Mohler, D. L; Shen, G. *Org. Biomol. Chem.* **2006**, *4*, 2082. (b) Tahtaoui, C.; Parrot, I.; Klotz, P.; Guillier, F.; Galzi, J. L.; Hibert, M.; Ilien, B. *J. Med. Chem.* **2004**, *47*, 4300.

(13) (a) Bogaschenko, T.; Basok, S.; Kulygina, C.; Lyapunov, A.; Lukyanenko, N. *Synthesis* **2002**, *15*, 2266. (b) Mlinaric-Majerski, K.; Kragol, G. *Tetrahedron* **2001**, *57*, 449.

(14) Whalen, L. J.; Halcomb, R. L. *Org. Lett.* **2004**, *6*, 3221.

(15) Heo, J.-N.; Holson, E. B.; Roush, W. R. *Org. Lett.* **2003**, *5*, 1697.

(16) Lindberg, J.; Stralfors, P.; Konradsson, P. *Tetrahedron* **2002**, *58*, 4245.

(17) Amer, H.; Hofinger, A.; Puchberger, M.; Kosma, P. *J. Carbohydr. Chem.* **2001**, *20*, 719.

(18) Cowan, J. A.; Ohyama, T.; Wang, D. Q.; Natarajan, K. *Nucleic Acids Res.* **2000**, *28*, 2935.

(19) Blount, K. F.; Zhao, F.; Hermann, T.; Tor, Y. *J. Am. Chem. Soc.* **2005**, *127*, 9818.

(20) Ida, T.; Okamoto, R.; Shimauchi, C.; Okubo, T.; Kuga, A.; Inoue, M. *J. Clin.Microbiol.* **2001**, *39*, 3115.

(21) Rasheed, J. K.; Anderson, G. J.; Yigit, H.; Queenan, A. M.; Doménech-Sánchez, A.; Swenson, J. M.; Biddle, J. W.; Ferraro, M. J.; Jacoby, G. A.; Tenover, F. C. *Antimicrob. Agents Chemother.* **2000**, *44*, 2382.

(22) Revuelta, J.; Vacas, T.; Torrado, M.; Corzana, F.; Gonzalez, C.; Jiménez- Barbero, J.; Menendez, M.; Bastida, A.; Asensio, J. L. *J. Am. Chem. Soc.* **2008**, *130*, 5086.